New hope for cancer patients: experimental drug aims to stop dangerous blood clots

NCT ID NCT07493304

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis or pulmonary embolism. Researchers will monitor safety, side effects, and how well the drug prevents new clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm neoplasm pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VENOUS THROMBOEMBOLISM (VTE)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bioresearch Partner- Hialeah Hospital
RECRUITING

Hialeah, Florida, 33013, United States
El Paso Medical Research Institute (Medresearch Inc)
RECRUITING

El Paso, Texas, 79902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.